2401 W.Belvedeve Avenue, Schapiro Building, Suite 203
Baltimore MD 21215
PyroDex’s service to biopharmaceutical manufacturers of injectable medicines and implantable medical devices consists of screening these parenteral drugs and implantable devices for microbial contaminants and chemicals known as pyrogens, using technologies that do not rely on the use of laboratory animals or animal products. Manufacturers of medical drugs and devices are required by regulatory agencies worldwide to test for product safety and quality assurance prior to the release of therapeutic products into the market. PyroDex will use an automated MAT (monocyte activation testing) process to perform these texts; the MAT is an FDA-approved screening procedure.